Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Breast 1

Conditions

Lymphoma, Non-Hodgkin 8Neoplasm Metastasis 6Breast Neoplasms 5Neoplasms 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × copanlisib × Clear all
NCT04042051 2025-07-22

Panthera

Cancer Trials Ireland

Phase 1 Terminated
2 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01411410 2017-10-11

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Bayer

Phase 1 Completed
55 enrolled
Tumor-Agnostic

Neoplasms

NCT00962611 2017-10-06

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Bayer

Phase 1 Completed
57 enrolled
Tumor-Agnostic

Neoplasms

NCT01392521 2015-04-17

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

Bayer

Phase 1 Completed
64 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡